NVS catalyst calendar
Clinical trials led by listed companies, by the completion date the sponsor registered on ClinicalTrials.gov, soonest first, from today. Most future dates are the sponsor's estimate and can move.
- Completion LockedPhase 1NCT07465653A Safety and Tolerability Study of HJB647 in Heart Failure Participants With Reduced Ejection FractionNovartis Pharmaceuticals · Heart Failure With Reduced Ejection FractionRecruitingNVSLead
- Enrollment
- Locked
- Primary completion
- Dec 8, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1NCT07626281Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a New Formulation of Inclisiran Containing Polysorbate 80...Novartis Pharmaceuticals · Inclisiran FormulationRecruitingNVSLead
- Enrollment
- Locked
- Primary completion
- Dec 21, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1NCT07644364HJB647 Phase 1b Study in Japanese Healthy Participants With Elevated Blood Pressure and Patients With HypertensionNovartis Pharmaceuticals · Elevated Blood PressureRecruitingNVSLead
- Enrollment
- Locked
- Primary completion
- Dec 25, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1NCT04857372A Phase I Study of IAG933 in Patients With Advanced Mesothelioma and Other Solid TumorsNovartis Pharmaceuticals · MesotheliomaActive, not recruitingNVSLead
- Enrollment
- Locked
- Primary completion
- Jan 7, 2027Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1/Phase 2NCT04699188Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C MutationNovartis Pharmaceuticals · KRAS G12C Mutant Solid TumorsActive, not recruitingNVSLead
- Enrollment
- Locked
- Primary completion
- Jan 25, 2027Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1NCT07174063A Phase I Study of JSB462 (Luxdegalutamide) in Japanese Patients With Metastatic Prostate CancerNovartis Pharmaceuticals · Metastatic Prostate Cancer (mCRPC)Active, not recruitingNVSLead
- Enrollment
- Locked
- Primary completion
- Jan 29, 2027Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1NCT05552469Dose Optimization and Expansion Study of DFV890 in Adult Patients With Myeloid DiseasesNovartis Pharmaceuticals · Myeloid DiseasesActive, not recruitingNVSLead
- Enrollment
- Locked
- Primary completion
- Feb 1, 2027Sponsor estimate
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 7 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerHow to read this calendar
Completion dates as registered on ClinicalTrials.gov by the sponsor, for trials Signal8 links to a listed company. Most future dates are the sponsor's estimate and move. A completion date is when the last participant is measured, not when results are announced.
The window starts today. A date the sponsor registered to the day is listed when it falls inside the window; a date that has already passed is never listed as upcoming, even when the sponsor has not updated it yet. A date registered to the month only (shown as, say, Dec 2026) could be any day of that month, so it is listed only when the whole month falls inside the window. TrialScanner never adds a day the sponsor did not register.
By default the list shows trials where a listed company is the lead sponsor. Trials a listed company only collaborates on (as a partner, drug supplier or contract research organization) are added with the role filter, and every company is labelled Lead or Collaborator.
Free readers see the first 25 trials of any filter and windows up to 90 days, with the trial, phase, status, sponsor and primary completion. Enrollment, interventions, the start and completion dates, longer windows and later pages are part of the plan. See the methodology.